ARTICLE | Company News
Mbiotec, Helmholtz Center for Infection Research deal
March 2, 2009 8:00 AM UTC
MBiotec received exclusive, worldwide rights to develop and commercialize the center's MALP-2S and its derivatives to treat cancer. The synthetic analog of MALP-2, a lipopeptide from Mycoplasma ferme...